Calidi Biotherapeutics Executes 1-for-16 Reverse Stock Split — Calidi Biotherapeutics, Inc.

Event summary

Calidi Biotherapeutics will implement a 1-for-16 reverse stock split effective July 31, 2026.
The move was approved by shareholders on June 12, 2026 and finalized by the board on July 15, 2026.
Shares will trade under the same ticker (CLDI) but with a new CUSIP number post-split.
Fractional shares will be rounded up to whole shares at the participant level.

The big picture

Reverse splits are typically a last-resort measure for micro-cap biotechs to avoid delisting, but Calidi frames this as a strategic move to optimize trading dynamics. The company's focus on systemic delivery of genetic medicines positions it in the competitive oncology space, where capital efficiency will be critical. With CLD-401 targeting high-unmet-need indications, investors will scrutinize whether this structural change signals operational constraints or simply aligns with long-term growth plans.

What we're watching

Market Perception Shift: How the reverse split affects institutional investor participation and liquidity.
Pipeline Progress: Whether CLD-401's IND-enabling studies maintain momentum amid capital restructuring.
Execution Risk: The pace at which Calidi can translate its RedTail platform into clinical-stage assets post-split.